Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

Senate Blocks Medicare Drug Price Negotiation Bill From Floor Vote

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Sen. Baucus’ effort to simply strike the non-interference clause, rather than requiring negotiations, did not garner enough support to force a vote.

You may also be interested in...



HHS Price Negotiations For Part D Not A Problem For Medco, CEO Snow Says

Medco is not worried about the possibility that the federal government may step in to negotiate drug prices for the Medicare Part D program, according to CEO David Snow

HHS Price Negotiations For Part D Not A Problem For Medco, CEO Snow Says

Medco is not worried about the possibility that the federal government may step in to negotiate drug prices for the Medicare Part D program, according to CEO David Snow

Higher Part D Premiums Whet Waxman’s Appetite For HHS Price Negotiation

Increasing Part D premiums have caught the eye of Rep. Henry Waxman, who sees them as further evidence that HHS would do a better job of negotiating drug prices for Part D than the private sector

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By